INTREPID Alliance

The INTREPID Alliance is a not-for-profit consortium of innovative biopharmaceutical companies and associations committed to accelerating antiviral research, aiming to ensure that we have a stronger pipeline and are better prepared to respond to future pandemic and endemic threats.

intrepidalliance.org

Overview

The experience of the COVID-19 pandemic demonstrated the importance of focusing on innovation across a full range of medical countermeasures, including tests, vaccines and treatments.

The INTREPID Alliance aims to accelerate the development of new treatments for emerging viral pandemic agents through facilitating early science and R&D, policy and advocacy, and stakeholder engagement. Led by a not-for-profit consortium of innovative biopharmaceutical companies and associations and working with the public, private and not-for-profit sectors, INTREPID works to bridge key gaps and unmet needs to ensure delivery of antiviral solutions to viral pathogens with the greatest pandemic potential.

INTREPID was launched in March 2023 at a high-level summit bringing together more than 100 thought leaders in virology and global health.

Antiviral pipeline

INTREPID publishes a list of promising antiviral compounds based on publicly available information and derived from a global landscape assessment and scientific evaluation.

INTREPID monitors and evaluates the wide range of innovative antiviral compounds and projects being researched around the world by academia, government, non-governmental organizations and the private sector for infections with pandemic potential, including coronaviruses, or viral families of concern such as filoviruses. The listed compounds include those that the experts assess to be able to proceed quickly into late-stage clinical development on the onset of a new pandemic.

INTREPID’s latest review of the global antiviral R&D landscape reveals that beyond Coronaviridae, only 27 antiviral compounds are in clinical development to tackle 12 viral families and their multiple diseases of greatest pandemic concern. Furthermore, there are no clinical development efforts underway for 4 viral families of pandemic potential (Paramyxoviridae, Hantaviridae, Peribunyaviridae, and Togaviridae).

Antiviral pipeline

INTREPID Alliance conducts a global landscape assessment of antiviral compound R&D. The landscape analysis intends to aid in the identification of clinical (e.g., Phase 2/3 ready) and preclinical antivirals aligned with the 100 Days Mission and highlight gaps in the pipeline.

Antiviral Toolbox

The Antiviral Toolbox is an open-access resource to support the global research community in its efforts toward filling the gaps in antiviral R&D that is critical to global health security and the protection of communities worldwide. This curated platform provides easy access to a focused collection of tools and publications, including a Registry of Antiviral Compound Libraries, to help catalyze the identification and development of small-molecule antivirals.

The key components within the INTREPID Alliance Antiviral Toolbox include:

Registry of Antiviral Compound Libraries: A curated list of accessible compound libraries for antiviral screening sourced from publicly disclosed academic institutions, corporate, and commercial vendor listings.
Antiviral Development Landscape: INTREPID’s bi-annual landscape report and interactive pipeline, along with deep-dive topic reports, that provide a comprehensive analysis of small-molecule antiviral compounds in preclinical and clinical development globally.
Drug Development Tools: Essential resources, including the published INTREPID Alliance Target Compound Profiles,4 Target Product Profiles,5 and cell and animal models for specific viral families, available to help drug discoverers and developers at all stages of research.
Pro Bono Advisory Services: Opportunity for drug discoverers and developers to connect with INTREPID’s team of experts to discuss potential strategies and approaches to address challenges along their drug development journey.

Antiviral Toolbox

An open-access resource to help catalyze drug discovery for priority viruses of pandemic and endemic concern.

Enhanced early science collaboration

By working with partners in other sectors, members of the Alliance engage in early science collaboration, data sharing and capability development, to accelerate our understanding of viral targets and increase the likelihood of identifying promising chemical leads. INTREPID maintains an up-to-date landscape analysis to identify gaps and unmet needs in the complex and evolving antiviral R&D ecosystem.

Stakeholder engagement

By aligning on unmet needs in antiviral pandemic prepardness that are identified by stakeholders, INTREPID serves as a hub and convenor for cross-sector engagement.

Policy and advocacy

By working with governments, academia, and private and philanthropic organizations that share INTREPID’s goals to shape a favorable legislative and regulatory environment for novel antivirals, increasing our ability to rapidly mobilize confirmed and authorized antivirals in the event of the next pandemic.